Xeris Biopharma (XERS) Competitors

Protagonist Therapeutics (NASDAQ:PTGX) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Is PTGX or XERS more profitable?

Protagonist Therapeutics has a net margin of 24.88% compared to Xeris Biopharma's net margin of -13.01%. Protagonist Therapeutics' return on equity of 8.12% beat Xeris Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	24.88%	8.12%	7.41%
Xeris Biopharma	-13.01%	N/A	-8.00%

Does the media prefer PTGX or XERS?

In the previous week, Xeris Biopharma had 14 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 26 mentions for Xeris Biopharma and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.14 beat Xeris Biopharma's score of 0.87 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation & earnings, PTGX or XERS?

Protagonist Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$209.18M	16.68	$275.19M	$0.70	80.10
Xeris Biopharma	$246.03M	5.04	-$54.84M	-$0.21	-36.57

Do institutionals & insiders have more ownership in PTGX or XERS?

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts rate PTGX or XERS?

Protagonist Therapeutics presently has a consensus target price of $67.20, suggesting a potential upside of 19.85%. Xeris Biopharma has a consensus target price of $6.58, suggesting a potential downside of 14.28%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Xeris Biopharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has more risk & volatility, PTGX or XERS?

Protagonist Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Summary

Protagonist Therapeutics beats Xeris Biopharma on 14 of the 17 factors compared between the two stocks.